COPD Deserves the Attention; Glad ENTB's On It
I'm liking what I'm seeing in regards to the fight that finally seems to be going on in the obstructive pulmonary disease field. I've been a PA and a healthcare administrator (now relaxing by playing with OTCs and the like) and the hospital medical materials department I ran was constantly looking for ways to help the medical research folks get the tools they needed (it was at the Naval Medical Center in Bethesda, MD) so that they could try to "connect the dots" more effectively.
The issue with this field (as it is whenever a huge amount of data is circulating out there, whether it's medical intelligence or military intelligence or the like) is that separating the wheat from the chaff becomes hugely important. One can do it, using more traditional tools, but epidemiological data collection and analysis -- even with the best investigatory tools available -- is extremely difficult. However, an bioinformatics suite can make it easier by a full order of magnitude. That's what's exciting about ENTB's little innovation.
Certainly, I'm hoping it's a big seller on the market, not only because it looks to be highly effective and it'll make for a potential high-selling product, but (more importantly) it may finally have given researchers a way to begin to find that elusive needle in a haystack or even, the single tiny grain of sand in a 200-mile long stretch of beach, that's how it's thought that some of these disease processes work (at the microcellular level).
Given that, I think the company's looking good, and for all the right reasons.
News 
Market Data 
Discover 
